Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EAVI2020

Financiado

Cerrado

European AIDS Vaccine Initiative 2020

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce... ver más

31/12/2022

IMPERIAL COLLEGE O...

24M€

Presupuesto del proyecto: 24M€

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 29 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

PHC-09-2015: PHC 9 – 2015: Vaccine development f...

I+D

Cerrada hace 9 años

0% 95% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

29 Participantes

IMPERIAL COLLEGE OF SCIENCE...

6.29M€ | Lider

UOXF

2.36M€ | Participante

Universitätsklinikum Erlange...

564.02K€ | Participante

FUNDACIO HOSPITAL UNIVERSITA...

195.18K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EHVA European HIV Vaccine Alliance EHVA a EU platform for the... 28M€ Cerrado

SAF2015-66193-R UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA... 182K€ Cerrado

ADITEC Advanced Immunization Technologies 41M€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

SOLVE Sustainable COVID-19 Vaccination for Long-term Vaccine Immun... 9M€ Cerrado

SAF2008-02036 BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT... 655K€ Cerrado

Duración del proyecto: 87 meses Fecha Inicio: 2015-09-11
Fecha Fin: 2022-12-31

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 24M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous prime–boost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the risk curve in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores